ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2410

Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort

Bindee Kuriya1, Daming Lin2, Cheryl Barnabe3, Gilles Boire4, Boulos Haraoui5, Carol Hitchon6, Shahin Jamal7, J. Carter Thorne8, Diane Tin9, Janet E. Pope10, Edward Keystone11 and Vivian P. Bykerk12, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 4Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 5Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 6Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 7Department of Rheumatology, Vancouver Coastal Health, Vancouver, BC, Canada, 8Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, 9The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 10Medicine, Western University, London, ON, Canada, 11University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, 12Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Work Disability and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: To describe working status in an ERA population in the first year of disease, and factors associated with improved work productivity. 

Methods: Patients in the Canadian Early Arthritis Cohort who completed the Work Productivity and Activity Impairment (WPAI) questionnaire at baseline and month 12 (commencing in 2010) were included.  Differences in working status at baseline were compared using chi-square or student’s t-tests.  A change in employment status and overall activity impairment was calculated as change from baseline to month 12. A change in absenteeism (work hours missed) and presenteeism (impact of RA on work productivity) was only calculated for those working at baseline.  Multivariate logistic regression analyses tested whether age, sex, symptom duration, DAS28 score, HAQ-DI or treatment at month 6 were associated with improvements in WPAI domains. 

Results: Of 2524 patients in the cohort, 729 had completed at least one WPAI questionnaire.  Of these, 190 were eligible (423 did not have serial WPAI and 306 were missing month 6 variables for analysis).  At baseline, the 190 patients had mean age 56 years, symptom duration 5.6 months, baseline DAS28 score 4.85; 110 were in paid employment at baseline. Individuals not in paid employment at baseline less frequently had high school or college education, had lower income, were older, had moderate-to-high DAS28 scores, and demonstrated higher HAQ-DI scores. Improvements in WPAI domains are shown (Table).  Among working individuals, by 12 months, 78% had an improvement in working hours missed, 67% reported improved productivity and 72% had reduced activity impairments. The largest change occurred for absenteeism (9.57 fewer hours/week missed). Younger age (OR 0.93, CI 0.89-0.98), DAS28 remission (OR 10.52, CI 1.4-79) and higher HAQ-DI at month 6 (OR 4.01, CI 1.2-13.1) were associated with gaining employment by month 12. DMARD or biologic use at month 6 was not associated with change in WPAI domains but corticosteroid use was negatively associated with presenteeism (OR 0.23, CI 0.06-0.89). 

Conclusion: Differences in demographic and disease-related variables exist between ERA patients who are working versus those who are not.  The majority of working individuals show improvements in WPAI domains over time but establishing the minimum clinically important difference for these domains is needed to help guide clinical interpretability. The impact of disease activity and functional ability on work productivity warrants further exploration in larger samples. 

Table. Mean (SD) in WPAI domain scores at baseline, month 12 and change from baseline to month 12.   

 

 

Working hours missed due to RA in past 7 days? (0-100 hours)

In past 7 days, how much did RA affect productivity while working? (0-10 scale)

In past 7 days, how much did RA affect daily activities? (0-10 scale)

 

 

Improved

Not Improved

Improved

Not Improved

Improved

Not Improved

Working at baseline

(N=110)

N (%)

Baseline score

Month 12 score

Change in score

76 (78)

9.95 (8.51)

0.38 (1.75)

-9.57 (8.45)

21 (22)

0.58 (4.61)

1.71 (7.17)

1.13 (5.58)

55 (67)

4.69 (2.43)

1.51 (1.83)

-3.18 (1.87)

27 (33)

0.81 (1.49)

1.74 (2.40)

0.93 (1.44)

80 (72)

4.95 (2.38)

1.19 (1.42)

-3.76 (2.08)

30 (28)

2.47 (2.91)

3.70 (3.10)

1.23 (1.61)

Not working at baseline

(N=80)

–

–

–

–

53 (66)

5.66 (2.53)

1.70 (1.96)

-3.96 (2.43)

27 (34)

2.44 (2.69)

3.59 (3.33)

1.15 (1.94)


Disclosure:

B. Kuriya,
None;

D. Lin,
None;

C. Barnabe,
None;

G. Boire,
None;

B. Haraoui,

AbbVie,

2,

AbbVie,

5,

Amgen,

2,

Amgen,

5,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5,

Janssen Pharmaceutica Product, L.P.,

2,

Janssen Pharmaceutica Product, L.P.,

5,

Pfizer Inc,

2,

Pfizer Inc,

5,

Roche Pharmaceuticals,

2,

Roche Pharmaceuticals,

5,

UCB,

2,

UCB,

5;

C. Hitchon,
None;

S. Jamal,
None;

J. C. Thorne,
None;

D. Tin,
None;

J. E. Pope,
None;

E. Keystone,

Abbott, Amgen, AstraZeneca, BMS, F. Hoffmann-La Roche, Janssen, Lilly, Novartis, Pfizer Sanofi-Aventis, UCB,

2,

Abbott Laboratories, AstraZeneca, Biotest, BMS, F. Hoffmann-La Roche, Genentech, Janssen, Lilly, Merck, Pfizer, UCB,

5,

Abbott, AstraZeneca, BMS Canada, F. Hoffmann-La Roche, Janssen, Pfizer, UCB, Amgen,

8;

V. P. Bykerk,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/working-status-and-improvements-in-work-productivity-over-time-in-an-early-rheumatoid-arthritis-era-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.